. 2016 Jan 18;18:12. doi: 10.1186/s13075-016-0920-6

Table 2.

Results from multivariate GEE model to identify predictors of response

Variable	β (95 % CI)	P value
Age at baseline, years	−0.003 (−0.01, 0.004)	0.35
RA duration, years	0.001 (−0.01, 0.008)	0.84
Sex, male^a/female	−0.13 (−0.41, 0.16)	0.39
DAS28 at baseline	0.39 (0.30, 0.49)	<0.0005
Duration of anti-TNF therapy, weeks	0.02 (0.01, 0.03)	<0.0005
RAPA seropositivity, yes/no^a	−0.07 (−0.39, 0.25)	0.66
ACPA seropositivity, yes/no^a	0.10 (−0.28, 0.48)	0.61
Smoking status, never^a/past/current	−0.10 (−0.24, 0.05)	0.18
Concurrent methotrexate use, yes/no^a	0.43 (0.19, 0.68)	<0.0005
Concurrent prednisolone use, yes/no^a	−0.08 (−0.28, 0.11)	0.40
Type of anti-TNF therapy, ETN^a, ADA or INF	−0.08 (−0.18, 0.02)	0.12

β regression coefficient. ^aReference category for these variables in the generalized estimating equations (GEE) model, RA rheumatoid arthritis, DAS28 Disease Activity Score in 28 joints, RAPA rheumatoid arthritis particle agglutination, ACPA anti-citrullinated protein antibodies